Suppr超能文献

骨髓增生异常综合征和再生障碍性贫血患者HFE基因突变的研究

[Study on HFE gene mutations in patients with myelodysplastic syndromes and aplastic anemia].

作者信息

Nie Ling, Ai Xiao-Fei, Zheng Yi-Zhou, Li Qing-Hua, Yang Lin, Xiao Zhi-Jian

机构信息

The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2009 Apr;30(4):223-8.

Abstract

OBJECTIVE

To detect the incidence of the HFE gene C282Y and H63D mutations in patients with myelodysplastic syndromes (MDS) and aplastic anemia (AA), and analyze the relationship of these mutations with iron metabolism, and organs impairment from iron overload.

METHODS

The incidence of the C282Y and H63D mutations in 271 MDS, 402 AA patients and 1615 normal subjects was measured by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) combining with DNA sequencing. Iron metabolism parameters and iron overload indices were retrospectively compared between HFE gene mutation and unmutation groups in MDS and AA patients with no transfusion history.

RESULTS

No C282Y and C282Y/H63D compound mutation was detected in all the three groups. The incidence of H63D heterozygous and homozygous genotype did not significantly differ between AA cases and controls (9.7% vs 10.2%, 0.25% vs 0.24% respectively, both P > 0.05). The frequency of H63D heterozygous genotype in MDS patients was significantly lower than that in controls (4.1% vs 10.2%, P = 0.002). H63D homozygous was not found in MDS patients. In both MDS and AA patients with no RBC transfusion history, serum ferritin (SF), transferrin saturation value (TS), serum iron concentration (SI) were close to or higher than normal; and unsaturated iron-binding capacity (UIBC) value was significantly lower. There was no significant difference in SF, SI, TS values between HFE-mutation and -unmutation MDS patients. For AA patients, only the level of SI was significantly higher in HFE-mutant group than in -unmutation group [42.6 (24.6-60.4) micromol/L vs 32.0 (8.4-63.3) micromol/L, P = 0.011]. There was no significant difference in the values of liver enzyme, fasting blood sugar (FBS), abnormal electrocardiogram (ECG), peripheral blood indices between HFE-mutation and -unmutation MDS and AA groups (all P > 0.05).

CONCLUSION

The distribution of C282Y and H63D mutations has ethnic and genetic disparity, the frequency in Chinese population is lower than that in Caucasian. It seems that MDS and AA patients are susceptible to iron overload, in the diseases itself and the mutations of HFE gene are not the major factor for iron overload in the patients.

摘要

目的

检测骨髓增生异常综合征(MDS)及再生障碍性贫血(AA)患者中HFE基因C282Y和H63D突变的发生率,并分析这些突变与铁代谢及铁过载所致器官损害的关系。

方法

采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)结合DNA测序法检测271例MDS患者、402例AA患者及1615例正常对照者中C282Y和H63D突变的发生率。对无输血史的MDS和AA患者,回顾性比较HFE基因突变组与未突变组的铁代谢参数及铁过载指标。

结果

三组均未检测到C282Y及C282Y/H63D复合突变。AA患者组与对照组H63D杂合子及纯合子基因型发生率差异均无统计学意义(分别为9.7%对10.2%,0.25%对0.24%,P均>0.05)。MDS患者中H63D杂合子基因型频率显著低于对照组(4.1%对10.2%,P = 0.002)。MDS患者中未发现H63D纯合子。在无红细胞输血史的MDS和AA患者中,血清铁蛋白(SF)、转铁蛋白饱和度(TS)、血清铁浓度(SI)接近或高于正常;而未饱和铁结合力(UIBC)值显著降低。HFE基因突变与未突变的MDS患者SF、SI、TS值差异无统计学意义。对于AA患者,仅HFE突变组SI水平显著高于未突变组[42.6(24.6 - 60.4)μmol/L对32.0(8.4 - 63.3)μmol/L,P = 0.011]。HFE基因突变与未突变的MDS和AA组肝酶、空腹血糖(FBS)、异常心电图(ECG)、外周血指标值差异均无统计学意义(P均>0.05)。

结论

C282Y和H63D突变的分布存在种族及遗传差异,中国人群中的频率低于白种人。MDS和AA患者似乎易发生铁过载,疾病本身及HFE基因突变并非患者铁过载的主要因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验